Skip to main content
. 2023 Jul 6;8(9):1822–1830. doi: 10.1016/j.ekir.2023.06.021

Figure 1.

Figure 1

Renal flares in patient subgroups across belimumab dosage forms. Bars depicting proportions of patients who developed at least 1 de novo renal flare during follow-up in patient subgroups exposed to belimumab treatment of different dosage forms compared with patients from the same studies treated with placebo. IV, intravenous; SC, subcutaneous.